S. Srock

发表

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer

H. Lenz, A. Grothey, H. Hurwitz, 2018, British Journal of Cancer.

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.

D. Doval, J. Pierga, E. Alba, 2014, The Lancet. Oncology.

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.

F. Puglisi, G. Romieu, G. von Minckwitz, 2014, The Lancet. Oncology.

Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma

W. Wick, M. Preusser, D. Miles, 2016, Molecular Cancer Therapeutics.

Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients †

D. Niederwieser, R. Rohrberg, M. Herold, 2008, British journal of haematology.

Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL - a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy.

E. Van Cutsem, M. Ducreux, J. Tabernero, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL).

D. Niederwieser, T. Ittel, R. Naumann, 2004 .

A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.

X. Pivot, J. Pierga, I. Smith, 2014, Breast.

Impact of cardiac surgery using cardiopulmonary bypass on course of chronic lymphatic leukemia: a case-control study.

R. Hetzer, R. Sodian, E. Potapov, 2002, The Annals of thoracic surgery.

Long-term treatment with rituximab is feasible in selected patients with B-CLL: Response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy

D. Huhn, A. Neubauer, M. Herold, 2007, Leukemia & lymphoma.

Clinical relevance of CD95 (Fas/Apo-1) on T cells of patients with B-cell chronic lymphocytic leukemia.

T. Sieber, F. Schriever, F. Ringel, 2003, Experimental hematology.

Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.

P. Dreger, K. Kreuzer, C. Schmidt, 2001, Experimental hematology.

Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.

T. Ittel, R. Naumann, K. Höffken, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer

A. Bardelli, F. Penault-Llorca, S. McCall, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin’s lymphoma: initial experience

N. Avril, D. Munz, A. Pezzutto, 2005, European Journal of Nuclear Medicine and Molecular Imaging.

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer

H. Lenz, A. Grothey, H. Hurwitz, 2018, British Journal of Cancer.

A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial.

X. Pivot, J. Pierga, I. Smith, 2013 .

Incidence of brain metastases in patients treated with bevacizumab

W. Wick, D. Miles, F. Winkler, 2013 .

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia.

D. Huhn, A. Hinke, M. Hallek, 2001, Blood.

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences

P. Neven, M. Gnant, D. Cameron, 2023, JNCI cancer spectrum.

353OEFFICACY AND SAFETY IN TANIA, A RANDOMISED PHASE III TRIAL OF CONTINUED OR REINTRODUCED BEVACIZUMAB (BEV) AFTER 1ST-LINE BEV FOR HER2-NEGATIVE LOCALLY RECURRENT/METASTATIC BREAST CANCER (LR/MBC).

F. Puglisi, G. Romieu, G. von Minckwitz, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

352OEFFICACY AND SAFETY OF MAINTENANCE BEVACIZUMAB (BEV) WITH OR WITHOUT CAPECITABINE (CAP) AFTER INITIAL FIRST-LINE BEV PLUS DOCETAXEL (DOC) FOR HER2-NEGATIVE METASTATIC BREAST CANCER (MBC): IMELDA RANDOMISED PHASE III TRIAL.

D. Doval, E. Alba, J. Gligorov, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients †

D. Niederwieser, R. Rohrberg, M. Herold, 2008, British journal of haematology.

Efficacy outcomes with bevacizumab added to chemotherapy (bev+CT) compared with chemotherapy alone (CT) in left- and right-sided tumors in metastatic colorectal cancer (mCRC).

H. Lenz, A. Grothey, H. Hurwitz, 2018 .